Medyra Pharmaceutica

  India has emerged as a global powerhouse in oncology pharmaceutical manufacturing , with the market projected to grow by USD 2.02 billion at a CAGR of 19.8% between 2024 and 2029. This remarkable growth is driven by cost-effective manufacturing, cutting-edge research capabilities, and an extensive export network reaching over 150 countries worldwide. Market Overview and Growth Statistics The Indian pharmaceutical industry ranks as the third-largest globally by volume and seventh by value, contributing over 20% of global generic drug exports. In oncology specifically: Market Size Growth : USD 2.02 billion expansion expected by 2029 Growth Rate : 19.8% CAGR (2024-2029) Export Reach : 150+ countries Cost Advantage : Up to 80% lower than developed nations Export Value : USD 3.2 billion in oncology drugs (2023) Key Market Drivers 1. Increasing Cancer Prevalence Estimated 1.6 million new cancer cases in India by 2025 Growing ...

  India has emerged as a global powerhouse for high-quality oncology medicines, especially Paclitaxel. From strong manufacturing expertise to strict GMP compliance, Indian companies now supply Paclitaxel injections and API to more than 65+ countries. This guide helps buyers, hospitals, distributors, and tender agencies understand India’s Paclitaxel landscape and how to choose a trusted manufacturer.   What is Paclitaxel? (Quick Overview) Paclitaxel is a widely used chemotherapy injection for treating breast cancer, ovarian cancer, lung cancer, cervical cancer, and AIDS-related Kaposi Sarcoma. In India, it is available in multiple strengths — 30 mg, 100 mg, 300mg and 260 mg — typically supplied in multi-dose vials under strict cytotoxic handling protocols.   Why India is a Global Hub for Paclitaxel Manufacturing India's oncology ecosystem offers unmatched advantages: WHO-GMP & ISO-certified facilities Competitive pricing due to optimized...

  India has emerged as one of the most dynamic hubs for oncology pharmaceutical manufacturing. With rising global demand for advanced cancer treatments, several Indian companies are contributing significantly to research, development, and export of oncology medicines. In this updated guide, we present the top cancer drug companies in India , starting with a brand that is shaping the future of accessible oncology: Medyra Onco .   Medyra Onco – India’s Fastest-Growing Oncology Medicine Supplier Medyra Onco stands at the forefront of India’s oncology pharma landscape, offering a specialized supply network trusted by hospitals, distributors, and global partners. Why Medyra Onco Leads the List Dedicated Oncology Focus – We exclusively deal in cancer medicines, biosimilars, targeted therapies, and supportive care drugs. Wide Product Portfolio – Injectables, tablets, hormonal therapies, targeted therapy molecules, and critical supportive drugs....

  World of modern medicine, speed and precision matter—especially when dealing with bacterial infections that escalate quickly . Ofloxacin Infusion IP 100ml is one such solution that delivers fast, targeted relief from a broad spectrum of bacterial infections. As a trusted name in pharmaceutical excellence, Medyra Pharma is proud to offer high-quality Ofloxacin Infusion designed to meet clinical standards and deliver real results. In this blog, we break down what Ofloxacin Infusion IP 100ml is, its key uses, and why Medyra Pharma’s formulation stands out in a crowded market.   What is Ofloxacin Infusion IP 100ml? Ofloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic . It works by inhibiting bacterial DNA gyrase and topoisomerase IV—two critical enzymes bacteria need to replicate and repair their DNA. By blocking these enzymes, Ofloxacin stops bacterial growth and helps eliminate infections effectively. Ofloxacin Infusion IP 100ml is an intravenous (I...